of information in 21 CFR part 601 have been approved under OMB control number 0910–0338.

## **III. Electronic Access**

Persons with access to the internet may obtain the draft guidance at https:// www.fda.gov/drugs/guidancecompliance-regulatory-information/ guidances-drugs, https://www.fda.gov/ regulatory-information/search-fdaguidance-documents, or https:// www.regulations.gov.

Dated: October 11, 2022.

# Lauren K. Roth,

Associate Commissioner for Policy. [FR Doc. 2022–22617 Filed 10–17–22; 8:45 am] BILLING CODE 4164–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Meeting of the Tick-Borne Disease Working Group

**AGENCY:** Office of Infectious Disease and HIV/AIDS Policy (OIDP), Office of the Assistant Secretary for Health (OASH), Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice; addendum to 87 FR 56964 published on September 16, 2022.

**SUMMARY:** The Office of the Assistant Secretary for Health published a notice of an upcoming meeting of the Tick-Borne Disease Working Group (TBDWG) in the **Federal Register** on September 16, 2022. This addendum provides notice of an additional day added to the October 25, 2022 meeting. The 24th meeting of the TDBWG will now take place from October 24–25, 2022. The September 16th **Federal Register** notice can be accessed at *https:// www.federalregister.gov/documents/* 2022/09/16/2022-20088/meeting-of-thetick-borne-disease-working-group.

**DATES:** The public can view the meeting online via webcast on October 24 and 25, 2022 from approximately 9:00 a.m. to 5:00 p.m. ET (times are tentative and subject to change) each day. The confirmed times and agenda items for the meeting will be posted on the TBDWG web page at *https:// www.hhs.gov/ash/advisory-committees/ tickbornedisease/meetings/2022-10-25/ index.html* when this information becomes available.

**SUPPLEMENTARY INFORMATION:** As stated in the **Federal Register** notice dated September 16th, the public will have an opportunity to present their views to the TBDWG orally during the meeting's public comment session or by submitting a written public comment. Persons who wish to provide verbal or written public comment should review instructions at *https://www.hhs.gov/ ash/advisory-committees/ tickbornedisease/meetings/2022-10-25/ index.html* and respond by midnight October 17, 2022 ET.

## FOR FURTHER INFORMATION CONTACT:

James Berger, Designated Federal Officer for the TBDWG; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Rockville, MD 20852. Email: *tickbornedisease@hhs.gov.* Phone: 202– 795–7608.

Dated: September 30, 2022.

# James Berger,

Designated Federal Officer, HHS Tick-Borne Disease Working Group, Office of HIV/AIDS and Infectious Disease Policy.

[FR Doc. 2022–22589 Filed 10–17–22; 8:45 am]

BILLING CODE 4150-28-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

## Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Population Sciences and Epidemiology Integrated Review Group; Cardiovascular and Respiratory Diseases Study Section.

Date: November 8–9, 2022.

*Time:* 9 a.m. to 8 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Mohammed F A Elfaramawi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1007F, Bethesda, MD 20892, (301) 480–1142, *elfaramawimf@csr.nih.gov.* 

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Cancer and Hematologic Disorders Study Section.

Date: November 9–10, 2022.

*Time:* 8:30 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

Contact Person: Denise Wiesch, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3138, MSC 7770, Bethesda, MD 20892, (301) 437– 3478, wieschd@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small

Business: Renal and Urological Sciences. *Date:* November 10, 2022.

Time: 8 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Ganesan Ramesh, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2182 MSC 7818, Bethesda, MD 20892, (301) 827– 5467, ganesan.ramesh@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; RFA–OD– 22–002: Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed).

Date: November 10, 2022.

*Time:* 1 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Maureen Shuh, Ph.D. Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–4097, maureen.shuh@ nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 12, 2022.

#### Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–22585 Filed 10–17–22; 8:45 am] BILLING CODE 4140–01–P